Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 4:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 7,077 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Neoplasm Clear all
Terminated Phase 4 Interventional Results available

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

NCT04031885
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Abemaciclib, Fulvestrant, Standard Chemotherapy
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
55
States / cities
Avondale, Arizona • Phoenix, Arizona • Yuma, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 28, 2026, 4:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Compliance With Medical Testing Guidelines

NCT02430948
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer, Prostate Cancer, Colon Cancer, Lung Cancer
Interventions
Color-coded materials, Academic detailing, Standard support, No academic detailing
Other
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
30 Years to 89 Years
Enrollment
218 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2019 · Synced Oct 28, 2026, 4:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Breast and Cervical Cancer Educational Intervention for Latinas in Western New York

NCT01760850
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer
Interventions
educational intervention, questionnaire administration
Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
959 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Oct 28, 2026, 4:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model

NCT00468585
View directory record Official record
Conditions
Breast Cancer
Interventions
Capecitabine, Bevacizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2016 · Synced Oct 28, 2026, 4:06 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

NCT02484404
View directory record Official record
Conditions
Colorectal Neoplasms, Breast Neoplasms
Interventions
Olaparib, Cediranib, Durvalumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 28, 2026, 4:06 PM EDT
Completed No phase listed Observational

Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast Disease

NCT00898508
View directory record Official record
Conditions
Breast Cancer
Interventions
gene expression analysis, mutation analysis, proteomic profiling, reverse transcriptase-polymerase chain reaction, fluorescent antibody technique, immunohistochemistry staining method, laboratory biomarker analysis, liquid chromatography, mass spectrometry, medical chart review, quality-of-life assessment
Genetic · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
20 Years and older · Female only
Enrollment
563 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
3
States / cities
Beverly Hills, California • Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 28, 2026, 4:06 PM EDT
Completed Not applicable Interventional

Blue Note Therapeutics Product BNT 103 Usability and User Engagement

NCT05032404
View directory record Official record
Conditions
Breast Cancer Female
Interventions
BNT103
Device
Lead sponsor
Blue Note Therapeutics
Industry
Eligibility
35 Years to 55 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Oct 28, 2026, 4:06 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

NCT04557449
View directory record Official record
Conditions
Liposarcoma, Prostate Cancer, Advanced Breast Cancer, NSCLC (Non-small Cell Lung Cancer), Colorectal Cancer
Interventions
PF-07220060, Letrozole, Fulvestrant, Midazolam, Enzalutamide, Giredestrant, Tamoxifen
Drug · Combination Product · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
14
States / cities
Los Angeles, California • New Haven, Connecticut • Trumbull, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 28, 2026, 4:06 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

NCT07145255
View directory record Official record
Conditions
Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Lung Cancer (Non-Small Cell), Pancreas Cancer, Duct Cell Adenocarcinoma
Interventions
ADC
Drug
Lead sponsor
MBrace Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
San Francisco, California • Grand Rapids, Michigan • East Brunswick, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 28, 2026, 4:06 PM EDT
Completed No phase listed Observational Results available

Advanced MRI Sequences for Radiation Therapy Treatment Planning

NCT02340715
View directory record Official record
Conditions
Cancer
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 89 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Oct 28, 2026, 4:06 PM EDT
Completed Phase 1 Interventional

Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

NCT02635672
View directory record Official record
Conditions
Neoplasms
Interventions
VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda, VIP152 (BAY 1251152) 15 mg
Drug
Lead sponsor
Vincerx Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
13
States / cities
Springdale, Arkansas • Louisville, Kentucky • Silver Spring, Maryland + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 28, 2026, 4:06 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Prospective Study of Sensation and Satisfaction in Cancer and Transgender Mastectomy Patients

NCT06094257
View directory record Official record
Conditions
Sensation Disorders, Sensation, Phantom, Pain, Postoperative, Pain, Chronic, Numbness, Sensory Disorder, Sensory Defect, Phantom Pain, Phantom Sensation
Interventions
Sensory testing
Diagnostic Test
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2033
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 28, 2026, 4:06 PM EDT
Completed Not applicable Interventional

A Digital Health Intervention to Improve Symptoms and Physical Activity During Breast Radiation

NCT06772181
View directory record Official record
Conditions
Breast Carcinoma
Interventions
IM@Home Program, Medical Device Usage and Evaluation, Questionnaire Administration, Interview
Behavioral · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Seattle, Washington • Spokane Valley, Washington
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 28, 2026, 4:06 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Alcohol, Breast Cancer, and Metabolism

NCT07779967
View directory record Official record
Conditions
Alcohol Drinking, Ethanol Intoxication, Breastfeeding
Interventions
Low-alcohol level exposure, Breast-pumping time
Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2032
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 28, 2026, 4:06 PM EDT
Active, not recruiting Not applicable Interventional

Robotic vs. Open NSM for Early Stage Breast Cancer

NCT05720039
View directory record Official record
Conditions
Breast Cancer Female, Breast Cancer, Breast Cancer, Early-Onset, Breast Disease, Breast
Interventions
Robotic NSM, Open NSM
Device · Procedure
Lead sponsor
Intuitive Surgical
Industry
Eligibility
21 Years and older · Female only
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
15
States / cities
Irvine, California • Los Angeles, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 28, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Results available

Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer

NCT00054275
View directory record Official record
Conditions
Breast Cancer
Interventions
docetaxel, erlotinib hydrochloride
Drug
Lead sponsor
Paula Silverman, MD
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 28, 2026, 4:06 PM EDT
Completed Phase 1 Interventional

Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas

NCT00019019
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Melanoma (Skin), Ovarian Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carboxyamidotriazole, paclitaxel
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2006
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 28, 2026, 4:06 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Study of Breast Tissue in Women Not Previously Diagnosed With Breast Cancer Who Are Undergoing Fine Needle Aspiration

NCT00896636
View directory record Official record
Conditions
Breast Cancer, Healthy, no Evidence of Disease
Interventions
Random fine need aspiration (rFNA), Mammogram
Procedure · Other
Lead sponsor
Northwestern University
Other
Eligibility
35 Years to 60 Years · Female only
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 28, 2026, 4:06 PM EDT
Terminated No phase listed Observational

Patient Registry: Partial Breast Irradiation

NCT01127971
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
19 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Green Bay, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 28, 2026, 4:06 PM EDT
Recruiting No phase listed Observational

A Novel Approach Utilizing Organ Specific Age Proteomics

NCT06789653
View directory record Official record
Conditions
Breast Cancer
Interventions
p16INK4a mRNA level assessment, organ-specific protein signatures assessment
Diagnostic Test
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
22 Years to 66 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 28, 2026, 4:06 PM EDT
Completed Not applicable Interventional

Pilot Usability and Feasibility Testing on Kinect-Enhanced Training System for Lymphatic Exercises

NCT03999177
View directory record Official record
Conditions
Breast Cancer, Lymphedema
Interventions
Kinect-TOLF Training System
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 90 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2020 · Synced Oct 28, 2026, 4:06 PM EDT
Completed Phase 4 Interventional

Patient Navigation in the Safety Net:CONNECTeDD

NCT00613275
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer
Interventions
patient Navigation
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
4,038 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 15, 2016 · Synced Oct 28, 2026, 4:06 PM EDT
Completed No phase listed Observational

Cell Lines From High-Risk Breast Tissue

NCT00032201
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
20 Years to 80 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 28, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Results available

Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer

NCT02366130
View directory record Official record
Conditions
Breast Cancer
Interventions
Ra-223 dichloride, Denosumab, Hormone Therapy
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Oct 28, 2026, 4:06 PM EDT